GH Research (NASDAQ:GHRS) Share Price Crosses Above 200-Day Moving Average - Should You Sell?

Key Points

• GH Research shares rose above their 200-day moving average of $21.47, reaching $22.13 before closing around $21.50. The company has a $1.48 billion market capitalization, while its 50-day moving average remains higher at $24.21.
• Analyst sentiment is broadly positive, with 10 Buy ratings, one Hold, and one Sell, producing a consensus “Moderate Buy” rating and a $45.00 target price. However, ratings range widely, from Weiss Ratings’ “sell” to price targets of $40 and $65.
• GH Research beat quarterly EPS expectations, reporting a loss of $0.23 versus the estimated loss of $0.29, though analysts expect a full-year loss of $1.20 per share. Institutional investors own 56.9% of the stock, and the company is advancing GH001, an investigational psychedelic-based treatment for treatment-resistant depression.

GH Research PLC (NASDAQ:GHRS - Get Free Report)'s share price passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $21.47 and traded as high as $22.13. GH Research shares last traded at $21.50, with a volume of 345,103 shares traded.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Guggenheim lifted their price target on shares of GH Research from $34.00 to $40.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. New Street Research set a $65.00 target price on GH Research in a research report on Monday, August 10th. Zacks Research upgraded GH Research from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of GH Research in a report on Thursday, October 15th. Finally, HC Wainwright restated a "buy" rating on shares of GH Research in a research note on Monday, August 10th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $45.00.

GH Research Stock Performance

The company has a market cap of $1.48 billion, a P/E ratio of -21.50 and a beta of 1.32. The business has a fifty day simple moving average of $24.21 and a 200 day simple moving average of $21.47.

GH Research (NASDAQ:GHRS - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.06. Equities research analysts expect that GH Research PLC will post -1.20 EPS for the current year.

Hedge Funds Weigh In On GH Research

Several institutional investors have recently made changes to their positions in the stock. Troluce Capital Advisors LLC grew its stake in GH Research by 165.4% during the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company's stock worth $13,926,000 after buying an additional 617,260 shares during the last quarter. Braidwell LP bought a new stake in GH Research in the second quarter valued at $5,571,000. Renaissance Technologies LLC bought a new stake in GH Research in the first quarter valued at $290,000. Squarepoint Ops LLC bought a new stake in GH Research in the second quarter valued at $495,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of GH Research by 30.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 17,525 shares of the company's stock valued at $432,000 after acquiring an additional 4,106 shares during the period. 56.90% of the stock is owned by institutional investors.

GH Research Company Profile

GH Research plc is a clinical-stage biopharmaceutical company focused on developing novel therapies for psychiatric and neurological disorders. The company is headquartered in Dublin, Ireland, and conducts research and clinical development activities through its proprietary pipeline of psychedelic-based medicines.

Its lead program, GH001, is an investigational inhaled formulation of mebufotenin, also known as 5-MeO-DMT. GH Research has studied GH001 in patients with treatment-resistant depression, with the aim of developing a rapidly acting treatment that may provide meaningful improvements following a short course of administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.